- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00033904
Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Primary Objective:
- The primary objective of this study is to determine whether subjects randomized to receive adjuvant HSPPC-96 after surgical resection of locally advanced renal cell carcinoma at high risk of recurrence, have improved recurrence-free survival as compared to subjects with no adjuvant treatment.
Secondary Objective:
- Determine whether subjects randomized to receive HSPPC-96 have improved survival as compared to subjects with no adjuvant treatment.
- Further characterize the safety profile of HSPPC-96.
Studietype
Registrering
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Kortrijk, Belgia
-
Liege, Belgia
-
-
-
-
-
Quebec, Canada
-
-
Alberta
-
Calgary, Alberta, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
Victoria, British Columbia, Canada
-
-
Ontario
-
London, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
-
-
-
Alaska
-
Anchorage, Alaska, Forente stater
-
-
Arizona
-
Tucson, Arizona, Forente stater
-
-
California
-
Los Angeles, California, Forente stater
-
San Francisco, California, Forente stater
-
-
Colorado
-
Denver, Colorado, Forente stater
-
-
Connecticut
-
Farmington, Connecticut, Forente stater
-
-
Florida
-
Boca Raton, Florida, Forente stater
-
Miami, Florida, Forente stater
-
Tampa, Florida, Forente stater
-
-
Georgia
-
Atlanta, Georgia, Forente stater
-
-
Illinois
-
Chicago, Illinois, Forente stater
-
Maywood, Illinois, Forente stater
-
-
Iowa
-
Iowa City, Iowa, Forente stater
-
-
Kansas
-
Kansas City, Kansas, Forente stater
-
-
Louisiana
-
Gretna, Louisiana, Forente stater, 70056
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
-
-
Missouri
-
St. Louis, Missouri, Forente stater
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater
-
-
New York
-
Manhasset, New York, Forente stater
-
New York City, New York, Forente stater
-
Rochester, New York, Forente stater
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater
-
Winston-Salem, North Carolina, Forente stater
-
-
Ohio
-
Cincinatti, Ohio, Forente stater
-
Cleveland, Ohio, Forente stater
-
Columbus, Ohio, Forente stater
-
-
Oregon
-
Eugene, Oregon, Forente stater
-
Portland, Oregon, Forente stater
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater
-
Nashville, Tennessee, Forente stater
-
-
Texas
-
Ft. Worth, Texas, Forente stater
-
Houston, Texas, Forente stater
-
-
Vermont
-
South Burlington, Vermont, Forente stater
-
-
Virginia
-
Richmond, Virginia, Forente stater
-
-
Washington
-
Seattle, Washington, Forente stater
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater
-
-
-
-
-
Lille, Frankrike
-
Strasbourg, Frankrike
-
Toulouse Cedex, Frankrike
-
Villejuif Cedex, Frankrike
-
-
-
-
-
Haifa, Israel
-
Holon, Israel
-
Jerusalem, Israel
-
Tel-Hashomer, Israel
-
-
Zerifin
-
Beer-Yaacob, Zerifin, Israel
-
-
-
-
-
Oslo, Norge
-
Stavanger, Norge
-
-
-
-
-
Bialystok, Polen
-
Gdansk, Polen
-
Kielce, Polen
-
Krakow, Polen
-
Lublin, Polen
-
Szczecin, Polen
-
Warsaw, Polen
-
-
-
-
-
Barcelona, Spania
-
Madrid, Spania
-
Valencia, Spania
-
-
-
-
-
Bristol, Storbritannia
-
London, Storbritannia
-
-
-
-
-
Gothenburg, Sverige
-
Lund, Sverige
-
Umea, Sverige
-
Uppsala, Sverige
-
-
-
-
-
Vienna, Østerrike
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Pre-Surgery Inclusion Criteria:
- Primary-intact resectable renal cell cancer, without known distant metastasis and be scheduled to have surgery with curative intent;
- Tumor size greater than or equal to 5 cm OR macroscopic nodes OR renal vein thrombus OR vena cava thrombus by radiologic evaluation
- Performance status (Zubrod / ECOG-WHO scale)less than or equal to 1 and life expectancy of greater than three months, within 2 weeks of surgery.
- Women of child-bearing potential must have a negative urine or serum pregnancy test within 2 weeks of surgery.
- Signed written informed consent.
Pre-Surgery Exclusion Criteria:
- Prior chemo-, hormonal, immuno- or radiotherapy for renal cell cancer;
- History of primary or secondary immunodeficiency, or patients using immunosuppressive drugs, e.g. systemic corticosteroids, cyclosporin A;
- Current malignancies at other sites or previous other cancer within the last 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin;
- Embolization of the renal artery prior to nephrectomy;
- Known distant metastases;
- Active, uncontrolled infection or other serious medical illnesses.
Eligibility Assessment:
(between 2 weeks pre- and 4 weeks post-surgery)
Prior to randomization and entry into the tumor evaluation phase, all subjects must undergo testing to confirm that they are free of distant metastatic disease, and that they meet all other criteria.
Eligibility Criteria which must be assessed and confirmed prior to randomization:
- No evidence of metastatic or residual renal carcinoma as documented by all of the following: abdominal/pelvis CT scan; chest CT scan; and brain CT or MRI scan.
- Provide Antigenics with greater than or equal to 7 grams of viable tumor tissue
- Adequate bone marrow function.
- Adequate renal and hepatic function.
- Adequate cardiac function.
- Signed written informed consent.
- Patients must be willing to be followed during the course of tumor evaluation and follow-up phases.
- Male or female patients of child producing potential must agree to use adequate contraception during the treatment/observation phase of the study.
- Patients must not use any other investigational drug for four weeks prior to the start of the tumor evaluation phase and throughout the tumor evaluation phase of the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- C-100-12 Part I
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nyrecellekarsinom
-
Debiopharm International SARekrutteringPankreas duktal adenokarsinom (PDAC) | Kolorektal kreft (CRC) | Clear Cell Renal Cell Cancer (ccRCC)Frankrike, Australia
-
University of Michigan Rogel Cancer CenterFullførtNyrecellekarsinomForente stater
-
Universitaire Ziekenhuizen KU LeuvenFullførtForekomst av utvidet renal clearance | Risikofaktorer for økt renal clearanceBelgia
-
Second Affiliated Hospital of Guangzhou Medical...Hunan Zhaotai Yongren Medical Innovation Co. Ltd.RekrutteringAnti-kreft celle immunterapi | T Cell og NK CellKina
-
Andrew B AdamsBristol-Myers SquibbFullført
-
University Health Network, TorontoFullførtGlomerulær filtreringshastighet | Renal blodstrømCanada
-
Peking University People's HospitalUkjentNatural Killer Cell Medited ImmunitetKina
-
Center for International Blood and Marrow Transplant...Cellular Dynamics International, Inc. - A FUJIFILM CompanyAvsluttetiPS Cell Manufacturing and Banking
-
Oregon Health and Science UniversityFullført
-
Erling Bjerregaard PedersenUniversity of AarhusUkjentRenal rørtransportDanmark
Kliniske studier på autolog human tumor-avledet HSPPC-96
-
Agenus Inc.FullførtLymfom, follikulær | Lymfom, små lymfocytterForente stater
-
Agenus Inc.Avsluttet
-
Agenus Inc.AvsluttetNyrecellekarsinomForente stater, Canada